Cord Blood Registry, AMAG Pharmaceuticals deal

AMAG will acquire stem cell company Cord Blood Registry from private equity firm GTCR for $700 million in cash. CBR stores more than 600,000 preserved umbilical cord blood and tissue stem cell units. AMAG expects the deal to bolster its maternal health offerings. AMAG markets Makena hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women who are pregnant with one baby and have spontaneously delivered one preterm baby in the past. ...